Dr. Siu Fun Wong
Professor, Associate Dean of Assessment and Scholarship
- Office Location:
- Rinker Health Science Campus 261
- (714) 516-5858
- University of California, Los Angeles, Bachelor of Science
University of California, San Francisco, Doctor of Pharmacy
In addition to the degrees listed in the Education section above, Dr. Wong holds the following credentials: FASHP and FCSHP. Dr. Siu Fun Wong is Associate Dean of Assessment and Scholarship, and a Full Professor at Chapman University School of Pharmacy.
Prior to joining the school, Dr. Wong joined Western University in 1997 as one of the founding faculty where she became the first tenured Professor of Pharmacy Practice at Western University. Dr. Wong also maintains her affiliation with UCI and was promoted to Clinical Professor of Medicine at UCI College of Medicine where she teaches anti-cancer pharmacology to the oncology fellows, medical students, and undergraduate students since early 1990s. In 2010, Dr. Wong joined Loma Linda University (LLU) and was appointed Professor of Pharmacotherapy and Outcomes Science at the School of Pharmacy until March of 2013 where she taught the oncology course and research-related topics. During her tenure at LLU, Dr. Wong established an innovative oral chemotherapy management clinic at LLU Cancer Center in 2011 that integrates patient care and outcome research.
She earned her Bachelor of Science degree in Biochemistry from the University of California, Los Angeles followed by Doctor of Pharmacy degree from the University of California, San Francisco (UCSF) School of Pharmacy. She completed a clinical residency at the University of California, Irvine (UCI) Medical Center where she stayed to develop the oncology pharmacy program and the Infusion Center Pharmacy at the Chao Comprehensive Cancer Center delivering direct patient care and actively engaged in clinical research.
Since the early 1990’s Dr. Wong continues to conduct regional, national, and international research focusing on symptom control in oncology which she received grant funding from federal and pharmaceutical sponsors.
In addition to teaching and research, Dr. Wong has assumed leadership and active participant roles in various national professional organizations including Hematology Oncology Pharmacy Association, California Society of Health-Systems Pharmacists, Southwest Oncology Group, and the National Cancer Institute. In addition to being the founding chair of the SWOG Pharmaceutical Sciences Committee since 1994, she was appointed SWOG Leader of Pharmaceutical Sciences since 2008 where she works with SWOG investigators and leaders on all pharmaceutical-related issues during protocol development and implementation processes. Dr. Wong also co-chair the Drug Development Task Force at the National Cancer Institute since 2012. Dr. Wong served as an expert examiner for the California Board of Pharmacy for 8 years and was subsequently nominated to join the NAPLEX Review Committee at the National Associate of Boards of Pharmacy since 2003. She has presented and published her research and practice model at national and international meetings. Dr. Wong is also an invited speaker nationally and internationally.
Dr. Wong’s awards include; Western University College of Pharmacy Preceptor of the Year Award (2009), Western University College of Pharmacy Faculty Service Award (2008), Orange County Society of Health System Pharmacists Pharmacist of the Year Award (1999), American Society of Health-System Pharmacists Practitioner Recognition Award (1998), UCI Incentive Award (Bone Marrow Transplantation Program) (1996), University of California, San Francisco School of Pharmacy Preceptors of the Year Award (1995), California Society of Hospital Pharmacists Practitioner Recognition Award (1993), UCI A&PS Achievement Award (1990 & 1991)
p>Dr. Wong has been a resident of Orange since 1988. She is elated and proud to be a member of the founding team of the first pharmacy school in her home town.
Dr. Wong’s primary research interest is in supportive care in oncology where she conducts studies to optimize the management of adverse events experienced by the cancer patients with the intent to improve patient’s quality-of-life. Her current research theme is in the management of papulopustular skin rash in cancer patients receiving epidermal growth factor receptor (EGFR) inhibitors. Currently she is conducting a study to validate a patient self-reporting Functional Assessment of Cancer Therapy (FACT-EGFR) at 48 sites nationally through SWOG cooperative group. The next phase of the study will be a randomize double-blind clinical study to evaluate the efficacy and safety of a topical cream in the treatment of the skin rash which also includes the translational research component to explore predictive biomarkers and innovative method to obtain biospecimens. Dr. Wong also conducts outcomes research to seek for development of best practice model in cancer patient care. Dr. Wong brings her expertise in drug development, pharmacotherapy, and outcome research in cancer populations to collaborate with the SWOG investigators and at other inter-professional settings.
- Recent Creative, Scholarly Work and Publications
Wong SF, Bales, CA, & Hurtado, K. Chapter 27: Investigational Agents: Procurement, Accountability and Administration of Research Study Drug. Manual for Clinical Trials Nursing. Oncology Nursing Press, Inc., 3rd edition, 2016:259-270.
Wong SF, Bounthavong M, Nguyen C, Chen T: “Outcome Assessments and Cost Avoidance of a Comprehensive Oral Chemotherapy Management Clinic”. Journal of National Comprehensive Cancer Network. Journal of National Comprehensive Cancer Network 2016 March 14(4): 279-285.
Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez, E.: “Implementation and Preliminary Outcomes of a Comprehensive Oral Chemotherapy Management Clinic”. American Journal of Health-System Pharmacists 2014 June 1; 71(11): 960-5.
Hershman D, Unger, J, Crew K, Moinpour C, Minasian L, Hansen L, Lew D, O’kane P, Wade JL, Wong, SF, Hortobagyi G, Meysken F, Albain K. “SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-induced Neuropathy During Adjuvant Breast Cancer Therapy”. Journal of Clinical Oncology 2013 June 10;31 (20):2627-33.
Chase DM, Wong SF, Wenzel L, & Monk B. Chapter 20:Palliative Care and Quality of Life. In ; DiSaia & Creasman, eds. Clinical Gynecologic Oncology, 8th edition. Philadelphia, PA. Elsevier-Saunders. 2012:597-630.
Wong SF & Mirshahidi H. “Management of Patients with CML: Practical Applications for Pharmacy Practitioners.” The Annals of Pharmacotherapy. 2011 June; 45:787-797.
Berenson J, Yelli O, Quiery A, Brady J, Patel R, Wong SF, Colbourn D, Gravenor D, Tiffany N, Shamasunder HK, and Wirtschafter E. “A Retrospective Study to Evaluate Bone Loss and Disease in Patients with Monoclonal Gammopathy of Undermined Significance”. Clinical Lymphoma, Myeloma & Leukemia 2011 August; 11 (4):336-41.